Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel

Multiple Sclerosis and Related Disorders

Volumn 3, Issue 4, 2014, Pages 513-519

  Phillips, J Theodore ^a   Hutchinson, Michael ^b   Fox, Robert ^c   Gold, Ralf ^d   Havrdova, Eva ^e  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c LERNER RESEARCH INSTITUTE   (United States)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adverse events; Dimethyl fumarate; Flushing; Gastrointestinal adverse events; Multiple sclerosis; Tolerability

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTIHISTAMINIC AGENT; DIMENHYDRINATE; DIPHENHYDRAMINE; DOMPERIDONE; FUMARIC ACID DIMETHYL ESTER; HISTAMINE H2 RECEPTOR ANTAGONIST; LOPERAMIDE; METOCLOPRAMIDE; ONDANSETRON; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ARTICLE; BOTHERSOMENESS; DAILY LIFE ACTIVITY; DELAYED RELEASE FORMULATION; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; FEEDING; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; NAUSEA AND VOMITING; PATIENT EDUCATION; PROPHYLAXIS; VOMITING;

EID: 84902515818     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2014.03.003     Document Type: Article

References (7)

1. V Devonshire, Y Lapierre, R Macdonell, C. Ramo-Tello, F. Patti, and P. Fontoura et al; GAP Study Group. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis Eur J Neurol 18 2011 69 77
2. RJ Fox, DH Miller, JT Phillips, M. Hutchinson, E. Havrdova, and M. Kita et al; CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis N Engl J Med 67 2012 1087 1097
3. R Gold, L Kappos, DL Arnold, A. Bar-Or, G. Giovanni, and K. Selmaj et al; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis N Engl J Med 367 2012 1098 1107
4. JT Phillips, and RJ. Fox BG-12 in multiple sclerosis Sem in Neurol 33 2013 56 65
5. K Selmaj, RJ Fox, R Gold, E. Havrdova, L. Kappos, and K. Raghupathi et al. Safety and tolerability of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the placebo-controlled studies [abstract] Mult Scler 18 Suppl. 4 2012 P484
6. S Sheikh, I Nestorov, H Russell, J. O'Gorman, R. Huang, and G. Milne et al. Safety, tolerability, and pharmacokinetics of BG-12 administered with and without aspirin: key findings from a randomized, double-blind, placebo-controlled trial in healthy volunteers [abstract] Neurology 78 Suppl. 1 2012 (P04.136)
7. SC Steinberg, RJ Faris, CF Chang, A. Chan, and M.A. Tankersley Impact of adherence to interferons in the treatment of multiple sclerosis. A non-experimental, retrospective, cohort study Clin Drug Invest 30 2010 89 100